Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAdministrative/Operational PolicyHumana prior auth PAL Michigan HMO D‑SNP | OpenPay…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHumanaPolicy N/A

    Humana HMO D-SNP Michigan prior authorization and notification list (PAL) for provider-administered medications

    Customize your policy alerts

    Sign up for all Humana policy alerts

    Know when Humana releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs prior authorization and notification requirements for medications administered in provider settings for Humana Dual Integrated HMO D-SNP members in Michigan; affects participating providers, delegated IPAs/risk networks, and pharmacies involved in office/clinic/outpatient or home administration.

    Policy Summary
    PayerHumana
    PolicyPrior authorization and notification list for provider-administered medications (Michigan HMO D-SNP)
    Policy CodePolicy N/A
    Change TypeAdministrative update (no material clinical changes)
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests online, by phone (866-461-7273), or by fax (888-447-3430) using the provided fax forms or contact methods.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    MichiganExplicitly governed state
    3Ways to initiate PA
    90 daysTemporary no-auth for active treatment
    866-461-7273Phone for PA requests
    888-447-3430Fax for PA requests
    Step therapyStep therapy noted

    Coverage criteria and medication list

    Medications requiring prior authorization or notification (partial list)

    The following is a partial excerpt of medications that require prior authorization or notification for Humana HMO D‑SNP Michigan plans, effective 2026-07-01. Coding, special flags and legend: * = New preauthorization requirement; † = New‑to‑market drug addition; ‡ = All shared HCPCS/NOC codes require a corresponding NDC on claims; ** = Step therapy required through a Humana‑preferred drug as part of preauthorization; †† = Preauthorizations reviewed by the Humana National Transplant Network (see contact info). Urgent/emergent services do not require prior authorization.

    Lunsumio (mosunetuzumab-axgb) — Billing Codes: J9350. * New preauthorization requirement; ‡ shared HCPCS/NOC rules.
    Lunsumio Velo (mosunetuzumab-axgb) — Billing Codes: J9350.
    Lutathera (lutetium Lu 177 dotatate) — Billing Codes: A9513.
    Luxturna (voretigene neparvovec-rzyl) — Billing Codes: J3398.
    Lyfgenia (lovotibeglogene autotemcel) — Billing Codes: J3394; †† review by Humana National Transplant Network as applicable.
    Lymphir (denileukin diftitox-cxdl) — Billing Codes: J9161.
    Lynozyfic (linvoseltamab-gcpt) — Billing Codes: J9601.
    Margenza — see full list for billing codes and flags.
    Ngenla (somatrogon-ghla) — Billing Codes: C9399, J3490, J3590.
    Niktimvo IV (axatilimab-csfr) — Billing Codes: J9038.
    Nivestym (filgrastim-aafi) — Billing Codes: Q5110; ** step therapy flag where indicated.
    Nplate (romiplostim) — Billing Codes: J2802.
    Nucala (mepolizumab) — Billing Codes: J2182.
    Nulibry — see full list for billing codes and flags.
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) — Billing Codes: A9607.
    Polivy (polatuzumab vedotin-piiq) — Billing Codes: J9309.
    Pombiliti (cipaglucosidase alfa-atga) — Billing Codes: J1203.
    Portrazza (necitumumab) — Billing Codes: J9295.
    Poteligeo (mogamulizumab-kpkc) — Billing Codes: J9204.
    Pralatrexate IV (pralatrexate) — Billing Codes: J9307; ‡ where applicable.
    Prevymis IV — see full list for billing codes and flags.
    Pyzchiva IV (ustekinumab-ttwe) — Billing Codes: Q9997; ** step therapy where indicated.
    Qalsody (tofersen) — Billing Codes: J1304.
    Qivigy (immune globulin intravenous, human-kthm) — Billing Codes: C9399, J3490, J3590, J1599; ‡ and ** flags where indicated.
    Qutenza (capsaicin/skin cleanser) — Billing Codes: J7336.
    Radicava (edaravone) — Billing Codes: J1301.
    Reblozyl (luspatercept-aamt) — Billing Codes: J0896; ** where indicated.
    Releuko (filgrastim-ayow injection) — Billing Codes: Q5125.
    Remicade (infliximab) — Billing Codes: J1745; ** where indicated.
    Remodulin (treprostinil injection) — Billing Codes: J3285; † where indicated.
    Renflexis (infliximab-abda) — Billing Codes: Q5104; ** where indicated.
    Retacrit (epoetin alfa-epbx) — Billing Codes: Q5106.
    Rethymic (allogeneic processed thymus tissue-agdc) — Billing Codes: C9399, J3490, J3590; †† and ‡ flags as noted.
    Riabni (rituximab-arrx) — Billing Codes: Q5123; ** where indicated.
    Rituxan Hycela (rituximab; hyaluronidase human) — Billing Codes: J9311; ** where indicated.
    Rituxan IV (rituximab) — Billing Codes: J9312; ** where indicated.
    Rolvedon (pegfilgrastim-cbqv) — see full list for billing codes and On‑body applicator flags (Udenyca Onbody referenced elsewhere as Q5111).
    Herceptin (trastuzumab) IV — Billing Codes: J9355; ** where indicated.
    Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) — Billing Codes: J9356.
    Hercessi IV (trastuzumab-strf) — Billing Codes: Q5146.
    Herzuma (trastuzumab-pkrb) — Billing Codes: Q5113.
    Hizentra (immune globulin) — Billing Codes: J1559; * / ** / ‡ flags as indicated in full list.
    Fulvestrant (Fresenius Kabi) — Billing Codes: J9394.
    Fulvestrant (Teva) — Billing Codes: J9393.
    Fyarro (sirolimus protein-bound particles for injectable suspension) — Billing Codes: J9331.
    Fylnetra (pegfilgrastim-pbbk) — Billing Codes: Q5130.
    GamaSTAN — Billing Codes: J1460, J1560; ‡ flag where applicable.
    GamaSTAN S/D — Billing Codes: J1460, J1560; ‡ flag where applicable.
    Gamifant (emapalumab-lzsg) — see full list for billing codes and requirements.
    Bkemv (eculizumab-aeeb) — Billing Codes: Q5152; **/‡ as applicable.
    Blenrep (belantamab mafodotin-blmf) — Billing Codes: C9399, J3490, J3590, J9999; ‡ flag.
    Blincyto (blinatumomab) — Billing Codes: J9039.
    Bomyntra (denosumab-bnht) — Billing Codes: Q5158; * / ‡ flags as applicable.
    Bortezomib (generic) — Billing Codes: J9046.
    Carvykti (ciltacabtagene autoleucel) — Billing Codes: Q2056; †† (transplant network review) and specialty submission routes apply.
    Casgevy (exagamglogene autotemcel) — Billing Codes: J3392; †† review applies.
    Cerezyme (imiglucerase) — Billing Codes: J1786; **/‡ flags where indicated.
    Cimerli (ranibizumab-eqrn) — Billing Codes: Q5128; * where indicated.
    Cimzia (certolizumab pegol) — Billing Codes: J0717; ** where indicated.
    Cinqair (reslizumab) — Billing Codes: J2786.
    Cinryze (C1 esterase inhibitor [human]) — Billing Codes: J0598; **/‡ flags where applicable.
    Columvi — see full list for billing codes and flags.
    Epkinly (epcoritamab-bysp) — Billing Codes: J9321.
    Epogen (epoetin alfa) — Billing Codes: J0885; ** and ‡ flags where applicable.
    Epygli IV (eculizumab-aagh) — Billing Codes: Q5151.
    Erbitux (cetuximab) — Billing Codes: J9055.
    Erwinase (crisantaspase) — Billing Codes: J9019; ‡ flag where applicable.
    Euflexxa — see full list for billing codes and requirements.
    Blood‑clotting factors (partial list) — examples include Nuwiq (simoctocog alfa) J7209; Obizur (antihemophilic factor [recombinant], porcine sequence) J7188; Profilnine (factor IX complex) J7194; Qfitlia (fitusiran) J7174 ** ‡; Rebinyn (Coagulation Factor IX [Recombinant], GlycoPEGylated) J7203; Recombinate J7192 ‡; Rixubis J7200; Roctavian (valoctocogene roxaparvovec-rvox) J1412; SevenFact (eptacog beta) J7212; Tretten J7181; Vonvendi J7179; Wilate J7183; Xyntha J7185; Xyntha Solofuse J7185.

    Billing codes and NDC requirements

    Sample HCPCS/CPT codes for listed medicationsHCPCSCovered
    Q2055Billing code listed for idecabtagene vicleucel (Abecma)
    J9264Billing code listed for paclitaxel-nab (Abraxane)
    J3262Billing code listed for tocilizumab (Actemra IV)
    J0791Billing code listed for crizanlizumab-tmca (Adakveo)
    Sample billing codes from listmixed
    Q5152Billing code listed for eculizumab-aeeb (Bkemv IV)
    C9399Miscellaneous drug code used for multiple products (e.g., Blenrep, Defitelio, Empaveli)
    J3490Unclassified drug code used for multiple products
    J9039Blinatumomab billing code (Blincyto)
    Q5158Denosumab-bnht billing code (Bomyntra/Conexxence)
    J9046Bortezomib billing code
    listed_medication_codesHCPCS | mixedCovered
    J9394fulvestrant (Fresenius kabi)
    J9393fulvestrant (Teva)
    J9331Fyarro (sirolimus protein-bound particles)
    Q5130Fylnetra (pegfilgrastim-pbbk)
    J1460GamaSTAN (immune globulin)
    J1569Gammagard (immune globulin)
    J9355Herceptin (trastuzumab IV)
    J9356Herceptin Hylecta (trastuzumab and hyaluronidase)
    J0638Ilaris (canakinumab)
    J9271Keytruda (pembrolizumab)
    Examples of drug-to-billing-code mappings in this extractHCPCS | mixedCovered
    J9350Lunsumio / mosunetuzumab-axgb
    A9513Lutathera / lutetium Lu 177 dotatate
    J3398Luxturna / voretigene neparvovec-rzyl
    J2562Mozobil / plerixafor
    J9203Mylotarg / gemtuzumab ozogamicin
    Example HCPCS/J/Q codes (partial)HCPCS
    Q9997Billing code listed for Pyzchiva IV (ustekinumab-ttwe)
    Selected J-codes (partial)CPT
    J9061Billing code listed for Rybrevant IV (amivantamab-vmjw)
    J1303Billing code listed for Ultomiris (ravulizumab-cwvz)
    Representative J/Q codes in this sectionHCPCS | mixedCovered
    J1303Ultomiris (ravulizumab-cwvz)
    Q5101Zarxio (filgrastim-sndz)
    Blood-clotting factor codesHCPCSCovered
    J7192Advate / Kogenate FS / Recombinate (antihemophilic factor) referenced
    J7207Adynovate
    Listed blood-clotting factor HCPCS codesHCPCSCovered
    J7212coagulation factor VIIa (recombinant)-jncw; eptacog beta (SevenFact) HCPCS code
    J7181coagulation factor XIII A-subunit [recombinant] (Tretten) HCPCS code
    J7179von Willebrand factor [recombinant] (Vonvendi) HCPCS code
    J7183von Willebrand factor / coagulation factor VIII complex [human] (Wilate) HCPCS code
    J7185antihemophilic factor [recombinant] (Xyntha / Xyntha Solofuse) HCPCS code
    Max diagnosis codes per authorization request
    Maximum diagnosis codesUp to 6 diagnosis codes per authorization request
    Where specifiedInclude primary and secondary diagnosis codes on PA submissions
    PurposeLimits the number of diagnosis codes transmitted with HCPCS/CPT codes for authorization determinations
    NDC billing requirement for shared HCPCS codes
    NDC billing requirementAll shared HCPCS and not otherwise classified (NOC) codes require a corresponding NDC to be billed on all claims

    How to request prior authorization and provider responsibilities

    Prior Authorization

    Prior Authorization Required

    Prior authorization (PA) is required for the medications listed on this Prior Authorization and Notification List (PAL). Providers must submit PA requests for provider-administered medications using one of the available channels. Requests may be submitted online via CoverMyMeds, by phone, or by fax (forms available on Humana's prior authorization for professionally administered drugs page). Billing codes (HCPCS/J-/Q-/C-codes or C9399/J3490/J3590 when noted) are provided next to each product in the list and must be used when submitting requests. Failure to obtain required PA may result in financial liability for the provider and reduced member benefits.

    • Online: CoverMyMeds (https://www.covermymeds.health/)
    • Phone: 866-461-7273 (TTY: 711), Monday - Friday, 8 a.m. - 11 p.m. ET
    • Fax: 888-447-3430 (request forms available on Humana's prior authorization for professionally administered drugs website)
    Denial Risk

    Legend and term definitions

    Prior authorization — definition
    DefinitionPrior authorization (preauthorization, precertification) is a process requiring the healthcare provider to obtain advance approval from the plan as to whether an item or service will be covered.
    When requiredRequired for medications delivered in provider office, clinic, outpatient or home settings listed in the PAL
    Relation to MedicareServices must meet Medicare coverage guidelines and be medically necessary per CMS
    Step therapy (Medicare Part B)
    DefinitionStep therapy (Medicare Part B) is a program that requires trial of Humana-preferred drugs (sometimes across benefits) before coverage of nonpreferred medications.
    Where to find detailsSee Humana's Medicare Part B Step Therapy Preferred Drug List (PDL) on Humana's provider prior authorization notification lists website
    Policy Summary
    PayerHumana
    PolicyPrior authorization and notification list for provider-administered medications (Michigan HMO D-SNP)
    Policy CodePolicy N/A
    Change TypeAdministrative update (no material clinical changes)
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests online, by phone (866-461-7273), or by fax (888-447-3430) using the provided fax forms or contact methods.
    SourceLink
    On This Page
    Coverage criteria and medication listBilling codes and NDC requirementsHow to request prior authorization and provider responsibilitiesLegend and term definitions
    ScopeApplies to shared HCPCS codes and HCPCS 'not otherwise classified' codes listed in the PAL
    Claim complianceProviders must include the corresponding NDC when filing claims for affected HCPCS/NOC codes
    NDC billing for shared HCPCS (restatement)
    Restatement of NDC billing ruleAll shared HCPCS and not otherwise classified codes require a corresponding NDC to be billed on all claims
    Legend usageThe '‡' symbol in the PAL denotes this NDC billing requirement
    Provider actionEnsure NDC is included on claim submissions for any item marked with the shared HCPCS/NOC notation

    Urgent/Emergent Services

    Urgent or emergent services do not require referrals or prior authorizations. However, services provided without prior authorization when one is normally required may be subject to retrospective medical necessity review and potential financial penalties under the provider contract or the member’s Evidence of Coverage.

    Step Therapy

    Step Therapy Guidance

    Step therapy may apply for certain Medicare Part B medications. Humana's Medicare Part B Step Therapy Preferred Drug List (PDL) — including preferred and nonpreferred medications and cross‑benefit strategies between Part B and Part D — is available on Humana's provider prior authorization notification lists website. Preferred status does not guarantee exemption from step therapy; review specific coverage criteria and the Part B Step Therapy PDL when processing requests.

    • Affected medications are noted with a step therapy indicator on the Medicare PAL
    • If the provider does not stock a preferred medication, it may be obtained from a pharmacy (see Humana mail-order and specialty pharmacy listings)
    • For questions: 800-457-4708 (TTY: 711), daily, 8 a.m. - 8 p.m. ET
    Note

    Transplant Review Process

    Certain preauthorization requests will be reviewed by the Humana National Transplant Network. Transplant-related products and services identified on the PAL carry the transplant review flag (††). These requests follow a special submission and review pathway distinct from routine PA processing.

    • Transplant review flag: †† — requests routed to Humana National Transplant Network
    • Transplant review may apply to new-to-market or transplant-related medications/services listed on the PAL
    Prior Authorization

    How to Request Prior Authorization (fax forms)

    Access and complete the Humana fax forms to request prior authorization or to provide notification for listed medications. Use the billing codes shown next to each product when submitting the request. Where a product is billed under a shared HCPCS or NOC code, include the corresponding NDC on claims as required.

    • Complete the appropriate Humana PA/notification fax form (available on Humana's prior authorization for professionally administered drugs website)
    • Include the billing code(s) listed for each product (HCPCS/J-/Q-/C-codes). When 'C9399, J3490, J3590' or similar NOC codes are listed, include the product NDC on the claim.
    • If step therapy applies, document prior trials of preferred therapies per coverage criteria
    Prior Authorization

    General Prior Authorization Request Instruction

    General instructions for prior authorization requests: except where noted, PA for medications may be initiated via CoverMyMeds, phone, or fax. The PAL is updated periodically; providers should verify current requirements on Humana's provider website. For medications requiring special handling (e.g., transplant-related, new-to-market), the PAL notes the alternate submission route or reviewer.

    • Online: CoverMyMeds — use for standard PA submissions when supported
    • Phone: 866-461-7273 (TTY: 711), Mon–Fri, 8 a.m. – 11 p.m. ET
    • Fax: 888-447-3430 — use the Humana PA/notification fax form for the specific medication
    Note

    Legend and Special Requirements

    Legend and special requirements used throughout the PAL: symbols adjacent to product names indicate special handling or requirements. Providers must observe these markers and the corresponding instructions when submitting PA requests.

    • * = New preauthorization requirement
    • † = New-to-market drug addition
    • ‡ = All shared HCPCS codes and NOC codes require a corresponding NDC to be billed on all claims
    • ** = Step therapy required through a Humana-preferred drug as part of preauthorization
    • †† = Preauthorization requests will be reviewed by the Humana National Transplant Network (see Transplant Review Process)
    Billing Rule

    Medication-specific Prior Authorization Instructions

    Medication‑specific prior authorization instructions are provided next to each listed product in the PAL. Each entry includes the product name, generic name (when applicable), the instruction to access Humana fax forms for PA/notification, and the billing code(s) to use on the PA request and claims. For shared/NOC billing scenarios, include the NDC on the claim and use C9399/J3490/J3590 (or the listed NOC) when instructed.

    • Examples of billing codes listed in the PAL: J1554, J0597, Q5152, J9039, Q5130, J9394, J9331, Q5130, J1460, J1560, J1289, J9355, J9356, Q5146, Q5113, J1559, Q5111, Q5138, J1304, J0218, J0588, J0897, J3299, J0218, J7209, J7188, J7194, J7174, J7203, J7192, J7200, J1412
    Documentation Required

    Prior Authorization Notes and Special Flags

    Prior authorization notes and special flags to observe when submitting requests: shared HCPCS/NOC codes require the product NDC on claims; some products are designated new preauthorization requirements or new-to-market and may have modified processes; step therapy indicators denote required trials of preferred therapies; transplant-related items require routing to the Humana National Transplant Network.

    • When a shared HCPCS or NOC code (e.g., C9399, J3490, J3590) is listed, include the specific product NDC on the claim.
    • Products marked with * or † may represent new PA requirements or new-to-market drugs—verify current criteria on Humana's provider website.
    • Products marked with ** require step therapy per Humana's Part B PDL.
    Note

    Transplant Review Contact for Preauthorization

    Transplant-related preauthorization submissions and contact information: preauthorization requests flagged for transplant review (††) will be reviewed by the Humana National Transplant Network. Providers should use the dedicated submission routes to ensure timely review.

    • Fax: 502-508-9300
    • Phone: 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time
    • Email: transplant@humana.com
    Cross-benefit noteStep therapy strategies may require preferred medication trials across Part B and Part D; consult the Part B Step Therapy PDL
     — Indicates new-to-market drug addition
    Symbol meaning† Indicates new-to-market drug addition
    UsagePlaced next to drug entries on the PAL to denote new-to-market products
    Provider actionRecognize † when reviewing PA requirements for recently introduced drugs
     —  Indicates HCPCS and NOC codes require a corresponding NDC
    Symbol meaning‡ Indicates HCPCS and NOC codes require a corresponding National Drug Code on all claims
    ScopeApplies to all shared HCPCS codes and HCPCS 'not otherwise classified' codes listed in the PAL
     — ** Indicates step therapy required through a Humana-preferred drug
    Symbol meaning** Indicates step therapy required through a Humana-preferred drug as part of preauthorization
    ApplicationEntries marked with ** require trial of a Humana-preferred drug per the Part B Step Therapy PDL during the PA process
    Provider guidanceFollow step therapy criteria noted on the PAL and Humana's Part B Step Therapy PDL when submitting PA
     — Indicates preauthorization reviewed by Humana National Transplant Network
    Submission optionsTransplant-network PAs can be submitted by fax to 502-508-9300, by phone at 866-421-5663 (Mon-Fri 7 a.m. - 7 p.m. CT), or by email to transplant@humana.com
    ScopeUsed for transplant-related and other specified items noted on the PAL
     — (alternate) Shared HCPCS codes require NDC
    Symbol meaning‡ Indicates shared HCPCS codes and not otherwise classified (NOC) codes require a corresponding NDC on all claims
    Alternate referenceRepeated across PAL entries and legend to emphasize NDC billing requirement for shared HCPCS/NOC codes
    Provider actionInclude the corresponding NDC on every claim for items marked with '‡' to ensure claim compliance
     — (alternate) Step therapy required through a Humana-preferred drug
    Symbol meaning** Indicates step therapy required through a Humana-preferred drug as part of preauthorization
    Alternate referenceUsed repeatedly in the PAL legend and next to drug entries to indicate step therapy requirement
    Provider instructionVerify step therapy requirements on the PAL and Part B Step Therapy PDL when preparing PA submissions
     — (alternate) Humana National Transplant Network review
    Submission methodsFax to 502-508-9300, phone 866-421-5663 (Mon-Fri 7 a.m.–7 p.m. CT), or email transplant@humana.com
    Applies toTransplant-related products and other items specified in the PAL legend
    Legend: Shared HCPCS/NOC codes require corresponding NDC
    Legend entryShared HCPCS or not otherwise classified codes require a corresponding NDC on claims (denoted by '‡')
    ImplicationClaims for items marked with this legend entry must include an NDC to be processed correctly
    Where shownDisplayed in the PAL legend and adjacent to affected drug entries
    Legend: Transplant Network PA submission options
    Legend entryPreauthorization requests reviewed by the Humana National Transplant Network can be submitted by fax, phone, or email (contacts provided)
    Contact detailsFax 502-508-9300; Phone 866-421-5663 (Mon-Fri 7 a.m. - 7 p.m. CT); Email transplant@humana.com
    ScopeApplies to transplant-reviewed preauthorizations noted in the PAL
    Legend: Step therapy required through Humana-preferred drug
    Legend entryStep therapy required through a Humana-preferred drug as part of preauthorization (denoted by '**')
    Provider actionFollow step therapy criteria on the PAL and Humana's Part B Step Therapy PDL when submitting a PA
    Where shownAppears in PAL legend and adjacent to affected drug entries
    Legend symbols used in the PAL
    Legend summarySymbols used in the PAL: '*' = new PA requirement; '†' = new-to-market drug; '‡' = shared HCPCS/NOC codes require NDC; '**' = step therapy required; '††' = transplant review
    PurposeSymbols quickly indicate special billing, step therapy, new-to-market, or transplant-review requirements for listed drugs
    Provider guidanceRefer to the legend when preparing PA/notification requests to identify special handling or submission paths
    Short tag: Step therapy required
    Short tag** = Step therapy required through a Humana-preferred drug
    UseDisplayed next to drug names in the PAL to signal step therapy requirement
    ActionConfirm preferred alternatives per Part B Step Therapy PDL before submitting PA for nonpreferred agents
    Short tag: Transplant Network review
    Short tag†† = Preauthorization requests for transplant reviewed by Humana National Transplant Network (fax/phone/email options provided)
    Contact infoFax 502-508-9300; Phone 866-421-5663; Email transplant@humana.com
    When usedTagged on PAL entries that require transplant-network review
    Step therapy flag ('**')
    Flag meaning'**' indicates step therapy required through a Humana-preferred drug as part of preauthorization
    ImplicationPA for products with this flag must consider preferred alternatives before approval
    ReferenceSee Humana's Part B Step Therapy PDL for preferred drug listings and criteria
    Shared HCPCS / NDC billing requirement ('‡')
    Flag meaning'‡' indicates shared HCPCS codes and NOC codes require a corresponding NDC to be billed on all claims
    Claim filingInclude NDC on claims for any item marked with '‡' to meet billing requirements
    Where notedUsed throughout the PAL legend and adjacent to affected product listings
    New drug / new preauthorization flags
    New PA flag'*' indicates a new preauthorization requirement; '†' indicates a new-to-market drug addition
    UsageSymbols appear in the PAL to call out new PA requirements or new-to-market products
    Provider actionCheck entries marked with '*' or '†' for any updated or recently added PA processes